William Blair analyst Andrew Brackmann has maintained their bullish stance on VCYT stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Brackmann has given his Buy rating due to a combination of factors, including Veracyte’s consistent outperformance versus expectations on key financial and operating metrics. The company exceeded consensus in first-quarter revenue, testing volumes for Afirma and Decipher, and AEBITDA, and management raised full‑year guidance slightly above the magnitude of the beat, supported by stronger‑than‑expected Afirma growth tied to workflow improvements.
Brackmann also highlights the strategic value of Veracyte’s near‑term pipeline catalysts, particularly the launches of TrueMRD for muscle‑invasive bladder cancer and the Prosigna LDT, whose OPTIMA trial readout at ASCO could underscore meaningful clinical differentiation. Although management has not yet built contributions from these products into current guidance, their launches, supported by Veracyte’s existing Decipher presence and focus on physician education, provide attractive optionality and validation for the broader minimal residual disease platform, reinforcing the positive long‑term outlook.
According to TipRanks, Brackmann is a 4-star analyst with an average return of 10.3% and a 44.44% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Guardant Health, and NeoGenomics.
In another report released today, Needham also reiterated a Buy rating on the stock with a $48.00 price target.